Suppr超能文献

泮托拉唑用于治疗与胃酸反流和阻塞性睡眠呼吸障碍相关的嗜睡。

Pantoprazole for sleepiness associated with acid reflux and obstructive sleep disordered breathing.

作者信息

Steward David L

机构信息

Department of Otolaryngology-Head and Neck Surgery and The Neuroscience Institute at the University of Cincinnati College of Medicine, Cincinnati, OH, USA.

出版信息

Laryngoscope. 2004 Sep;114(9):1525-8. doi: 10.1097/00005537-200409000-00003.

Abstract

OBJECTIVE

To determine the effectiveness of Pantoprazole (Wyeth Pharmaceuticals Inc., Philadelphia, PA) therapy for daytime sleepiness in patients with symptoms of acid reflux and obstructive sleep-disordered breathing (OSDB).

STUDY DESIGN

Prospective interventional cohort study.

METHODS

Twenty-seven adult subjects (67% men) with symptoms of acid reflux disease and mild to moderate OSDB were included in a 3-month study of proton pump inhibitor therapy (Pantoprazole 40 mg once daily). Primary outcomes included changes in daytime sleepiness, reflux symptoms, and bed partner assessment of snoring. Secondary outcomes included changes in snoring quantification, apnea, and apnea-hypopnea indices (AHI) with SNAP Laboratories (Glenview, IL) home sleep study and self-reported global symptom improvement.

RESULTS

At baseline, patients were typically middle-aged, obese men with mild to moderate sleep apnea (mean AHI = 15) with excessive daytime somnolence (mean Epworth Sleepiness Score = 13). After 3-month treatment with Pantoprazole, a statistically significant improvement was noted for daytime sleepiness (P = .002) and total reflux symptoms (P = .0006). Subjects also reported a significant reduction in reflux awakening them from sleep (P < .0001). Bed-partner assessment of snoring significantly improved (P = .03); however, no significant improvements were noted in snoring quantification, apnea, or AHI. When compared with a disease-severity matched historic placebo-control group, this cohort demonstrated a significantly greater reduction in daytime sleepiness (P = .04).

CONCLUSIONS

This cohort of subjects had significant improvements in daytime sleepiness and reflux symptoms, including reflux awakening from sleep, with Pantoprazole therapy. Further controlled studies are indicated to confirm these results. Improvement in daytime somnolence likely resulted from a reduction in reflux-related arousals because no improvements occurred in OSDB.

摘要

目的

确定泮托拉唑(惠氏制药公司,宾夕法尼亚州费城)治疗伴有胃酸反流症状和阻塞性睡眠呼吸障碍(OSDB)患者日间嗜睡的有效性。

研究设计

前瞻性干预队列研究。

方法

27名有胃酸反流疾病症状和轻至中度OSDB的成年受试者(67%为男性)纳入一项为期3个月的质子泵抑制剂治疗(泮托拉唑40毫克,每日一次)研究。主要结局包括日间嗜睡、反流症状的变化以及同床伴侣对打鼾的评估。次要结局包括通过SNAP实验室(伊利诺伊州格伦维尤)家庭睡眠研究对打鼾量化、呼吸暂停和呼吸暂停低通气指数(AHI)的变化,以及自我报告的整体症状改善情况。

结果

基线时,患者通常为中年肥胖男性,伴有轻至中度睡眠呼吸暂停(平均AHI = 15),并有日间过度嗜睡(平均爱泼华嗜睡量表评分 = 13)。经过3个月的泮托拉唑治疗后,日间嗜睡(P = 0.002)和总反流症状(P = 0.0006)有统计学意义的改善。受试者还报告说,反流导致他们从睡眠中醒来的情况显著减少(P < 0.0001)。同床伴侣对打鼾的评估有显著改善(P = 0.03);然而,在打鼾量化、呼吸暂停或AHI方面未发现显著改善。与疾病严重程度匹配的历史安慰剂对照组相比,该队列在日间嗜睡方面的减少更为显著(P = 0.04)。

结论

该队列受试者在接受泮托拉唑治疗后,日间嗜睡和反流症状,包括因反流从睡眠中醒来的情况有显著改善。需要进一步的对照研究来证实这些结果。日间嗜睡的改善可能是由于与反流相关的觉醒减少,因为OSDB没有改善。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验